CD274 and metastatic neoplasm: In Impower010 the greatest DFS benefit could be seen in the PD-L1 expression ≥50% group, but interestingly in Keynote-091 the PD-L1 ≥50% group did not show this benefit despite the results with pembrolizumab in metastatic disease [42, 43].